Wikisage, the free encyclopedia of the second generation, is digital heritage
Rufinamide: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 5: | Line 5: | ||
<small>"Rufinamide received the status of orphan drug for [[epilepsy]] in 2004 in Europe"</small> | <small>"Rufinamide received the status of orphan drug for [[epilepsy]] in 2004 in Europe"</small> | ||
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]</ref> | <ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]</ref> | ||
It is an inductor of [[Cytochrome P450|CYP 450]] | It is an inductor of [[Cytochrome P450|CYP 450]] | ||
| Line 14: | Line 13: | ||
[http://www.pharmawiki.ch/wiki/index.php?wiki=Rufinamid Pharmawiki:Rufinamid] | [http://www.pharmawiki.ch/wiki/index.php?wiki=Rufinamid Pharmawiki:Rufinamid] | ||
==[[ATC]]== | ==[[ATC]]== | ||
<gallery>File:Rufinamid.svg.png</gallery> | |||
https://www.whocc.no/atc_ddd_index/?code=N03AF03 | https://www.whocc.no/atc_ddd_index/?code=N03AF03 | ||
{{refs}} | |||
{{Wikidata|Q408565}} | {{Wikidata|Q408565}} | ||
[[Category:Anticonvulsants]] | [[Category:Anticonvulsants]] | ||
Latest revision as of 20:41, 20 March 2023
Lennox-Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconclusive. Otsuka et al. (2014) state rufinamide as an efficacious and well tolerated AED [1](cf. Alssad et Coren 2014) [2]
"Rufinamide received the status of orphan drug for epilepsy in 2004 in Europe" [3]
It is an inductor of CYP 450
Weblinks
ATC
https://www.whocc.no/atc_ddd_index/?code=N03AF03
